XORTX Therapeutics Inc. (XRTX)
- Previous Close
1.0600 - Open
1.0300 - Bid 0.9000 x 100
- Ask --
- Day's Range
1.0200 - 1.0800 - 52 Week Range
0.8020 - 3.1300 - Volume
41,536 - Avg. Volume
53,985 - Market Cap (intraday)
4.026M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1500 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.48
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
www.xortx.comRecent News: XRTX
View More
Performance Overview: XRTX
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX
View MoreValuation Measures
Market Cap
4.03M
Enterprise Value
1.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.21%
Return on Equity (ttm)
-83.06%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.31M
Diluted EPS (ttm)
-1.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47M
Total Debt/Equity (mrq)
1.16%
Levered Free Cash Flow (ttm)
-1.11M